IN BRIEF: Faron Pharmaceuticals fined EUR30,000 by Nasdaq Helsinki
5th Jun 2026 12:37
Faron Pharmaceuticals Ltd - Turku, Finland-based cancer drug developer - Says the Disciplinary Committee of Nasdaq Helsinki Ltd has imposed an EUR30,000 fine over breaches in 2024. The committee found that Faron breached the Nasdaq First North Growth Rulebook for Issuers of Shares, regarding "the obligation to disclose inside information without undue delay in certain matters". It also breached "good securities market practise" regarding "certain public statements made in a media interview". Faron notes that the committee dismissed two alleged breaches, including "importantly," the allegation that Faron had not organised its administration in the manner required for listed companies. Read More